source
- Ultragenyx gene therapy for Angelman syndrome fails Phase 3 trial, company to cut expensesAn experimental gene therapy targeting Angelman syndrome did not meet its primary endpoint in a Phase 3 study, according to Ultragenyx. The trial showed no difference between the therapy, GTX-102,…
- Abivax remains independent despite intense acquisition speculationBiotech merger activity is at record levels, yet the French company Abivax, which is developing the ulcerative colitis drug obefazimod, has not been bought. Rumors have floated about a potential $…